cyrilzakka/clinical-trials huggingface dataset:
Chemotherapy and Radiotherapy for Osteolymphoma

This trial is intended to determine the results obtained when standard treatment for Non Hodgkin's lymphoma is applied to the disease in a rare subtype which arises in bone. Patients in the study undergo a detailed assessment, then treatment with chemotherapy and radiotherapy, followed by close monitoring.

Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult. The term Osteolymphoma has been proposed to make searching easier in the future. Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available. Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included as good results have been obtained without using them. After treatment the patients are regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and AROLG.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed non-Hodgkin's lymphoma in a bony site
* Limited extraosseous disease
* Ann Arbor stage IE
* Age \>17
* ECOG performance status \<3
* Expected survival \> 6 months
* Patients capable of childbearing are using adequate contraception.
* Written informed consent

Exclusion Criteria:

* Previous radiotherapy
* Previous malignancy
* Medically unfit to undergo treatment
Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement

The purpose of this study is the investigate if pregabalin started a day before surgery and continued for 14 days post-operatively can reduce post-operative pain, relieve pre- and post-operative anxiety and sleep disturbances.


Eligibility Criteria:
Inclusion Criteria:

* The patient is undergoing a routine (i.e., expected to be uncomplicated) total primary or secondary hip replacement surgery performed under a standardized regimen of spinal anesthesia, and is expected to experience moderate to severe post-surgical pain in the absence of post-operative analgesia

Exclusion Criteria:

* The patient is undergoing a revision to a previous hip replacement procedure, hip replacement procedure further to a road traffic accident with multiple injuries, or a procedure expected to last longer than 4 hours
* The patient has a history of uncontrolled chronic disease or a concurrent clinically significant illness or medical condition, which in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results
Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This trial is studying the safety and effectiveness of autologous gp96 treatment of glioblastoma and to see how well it works in treating patients with newly diagnosed supratentoria glioma.


Eligibility Criteria:
Inclusion Criteria:

1. Able to read and understand the informed consent document; must sign the informed consent.
2. Aged 18 to 75 years old , sex is not limited
3. Newly Diagnosed supratentoria glioma, Must have undergone a at least a 80% resection
4. Availability of at least 1 g tumor sample.
5. Karnofsky functional status rating \> or equal to 70.
6. Adequate bone marrow function including the absence of lymphopenia (ANC \> 1,500/ mm3; Hemoglobin \> 10g/dL ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[AST\], alanine amino transferase \[ALT\] \<2.5 times institutional upper limit of normals \[IULNs\] ), and adequate renal function (BUN and creatinine \<1.5 times IULNs)
7. Agree to Surgical indications of Heart \& lung and without the coagulation system disease
8. Negative pregnancy test for female patients of childbearing potential
9. Agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration

Exclusion Criteria:

1. Inability to comply with study-related procedures
2. patient not suitable for Neurosurgery.
3. Unavailability of at least 6 doses of vaccine
4. Progression prior to vaccination as determined by the Principal Investigator
5. Patient with allergic constitution
6. Unstable or severe intercurrent medical conditions
7. Current diagnosis of Human Immunodeficiency Virus and Patients with active uncontrolled infection.
8. patients with any systemic disease needed to be treated with immunosuppressant or Corticosteroids.
9. any other clinical trials within 30 days pre-vaccination.
10. Female patients who are pregnant or breastfeeding
Evaluation of SNAP-Ed Online Modules to Improve Responsive Feeding Practices of Caregivers

Evaluation of three online modules developed by the Center for Childhood Obesity Research for caregivers of children ages 5-12 years old participating in SNAP-Ed programing.

the Center for Childhood Obesity Research developed three online modules for caregivers of children ages 5-12 years old who are participating in SNAP-Ed programming. These modules were developed to be used within the context of normal programming that participants will receive in any given year. The specific aim are as follows:

Aim #1: To examine acceptability of these modules by caregivers participating in SNAP-Ed programming. This will be assessed by evaluating acceptability questions answered by participants after completing the modules.

Aim #2: To examine the feasibility of these modules by caregivers participating in SNAP-Ed programming, assessed by \>60% completion rate of all three modules.

Online module content will focus on topics such as:

* Shared Responsibility of Feeding:
* Parent Provides, Child Decides
* Family Mealtimes
* Hunger and Fullness
* Avoiding use of controlling feeding practices

Eligibility Criteria:
Inclusion Criteria:

* Primary caregiver of a child between the ages of 2 to 16 years
* Over the age of 18
* English-speaking
* Have a reliable internet source and active email account so they can access the online modules

Exclusion Criteria:

* Are not the primary caregivers of a child between the ages of 2 to 16 years
* Are under the age of 18
* Are not English-speaking
* Do not have a reliable internet source or email address
Tranexamic Acid Effect in Pediatric

The study will compare mortality and blood transfusion amounts among severely polytraumatized pediatrics who did or did not receive tranexamic acid within 3 h of injury, based on Injury Severity Score (ISS) and indicators of coagulopathy and fibrinolysis.

Trauma is a leading cause of mortality in the pediatric population. In 2008, the American Academy of Pediatrics noted that trauma accounts for more deaths than all other causes combined . Bleeding remains the most preventable cause of death after trauma. A major recent advance was the recognition that coagulation defects are greatly responsible for the disproportional mortality caused by bleeding. Managing coagulation defects has become a forefront issue in trauma and novel strategies proposed include hemostatic resuscitation, adoption of massive transfusion protocols and other innovations , most with little evidence to support them. The exception is the proposal to administer tranexamic acid (TXA) to bleeding adult trauma patients.

To date, no medical treatment has been shown to reduce mortality in the setting of pediatric trauma; however, this evidence does exist in adults. Bleeding and coagulopathy due to trauma are associated with mortality in both adults and children. Clinical research has demonstrated a reduction in trauma-related mortality with early use of TXA in adult patients in both civilian and military settings . In adult patients with hemodynamic instability and ongoing bleeding, TXA is expected to save 1 in 67 lives . There is no scientific or biological reason to suggest that a similar mortality benefit will not be seen in pediatric trauma. The investigators feel the incorporation of TXA into pediatric trauma management has the potential to also significantly reduce mortality in children and youths, without increasing adverse events. This review explores the hematologic differences and similarities between injured children and adults, and the idea that TXA may be a novel and promising treatment in pediatric hemorrhagic trauma despite the current lack of evidence for its use in this setting.

TXA is an antifibrinolytic that reversibly binds to plasminogen at the lysine binding site, thus preventing the binding of plasmin (ogen) to fibrin and the subsequent degradation of fibrin . It is a generic, inexpensive medication used to prevent fibrin breakdown and reduce bleeding in various clinical settings (including orthopedic and cardiovascular surgery, post-partum hemorrhage, gastrointestinal hemorrhage, epistaxis, certain ophthalmologic conditions and other obstetric/gynecologic emergencies)

Eligibility Criteria:
Inclusion Criteria:

1. ISS ≥ 16
2. age 2-18 years
3. both genders
4. polytraum a

Exclusion Criteria:

1. age \< 2 OR \>18 years
2. period from injury to admission \>6 hours
3. ISS\<16
4. comorbidity with bleeding disorder, malignancy.
5. Patients receiving anticoagulant drugs.
Rétrospective Evaluation of the Performance and the Safety of the Endoscopic Mucosectomy With Anchorage

This safe and simple technique without extra cost would allow us to improve R0 resection ratio and so decrease relapses and the time between two different exams


Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years old
* Other rectal or colic résections from 10 to 30 mm into the past

Exclusion Criteria:

* Colitis, Crohn Disease or Ulcerative Colitis
* Intense fibrosis under the lesion
An Innovative Image-Based Method for Extensibility Assessment

This study uses a mixed-method design combining a quasi-experimental, single-group pre-post intervention with a methodological validation approach.

1. Quasi-experimental, single-group pre-post intervention:

   Participants will receive a standardized physical therapy protocol targeting scar contracture. After intervention, scar extensibility will be measured using traditional tools (Vancouver Scar Scale, tonometer) and a newly developed image-based method.
2. Methodological validation approach: The image-based method will be tested for:

   * Reliability (test-retest, inter-rater)
   * Validity (concurrent validity against established tools and construct validity)

Eligibility Criteria:
Inclusion Criteria:

* History of clinically diagnosed scar contracture following thermal burns.
* Presence of scars (≥6 months post-burn) to ensure stability for accurate assessment.
* Scars located on functionally mobile areas (e.g., limbs) where extensibility impacts daily activities.
* Willingness to undergo a standardized physical therapy intervention.
* Ability to provide informed consent and comply with all study procedures.

Exclusion Criteria:

* Active infection, unhealed wounds, or unstable scars at the assessment site.
* Diagnosed systemic diseases affecting collagen synthesis or wound healing (e.g., scleroderma, uncontrolled diabetes).
* History of experimental or non-standard scar treatment within the last 3 months.
* Severe cognitive impairments or communication barriers that interfere with understanding or participation.
* Pregnant or lactating women, due to hormonal influences on tissue healing and collagen metabolism.
* Concurrent participation in other physical therapy or rehabilitation studies targeting scar management.
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU), levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate (CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) \*1/\*1, \*1/\*6 or \*1/\*28.


Eligibility Criteria:
Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the colon or rectum.
2. Unresectable or recurrent colorectal cancer patient.
3. One or more measurable lesion in RECIST ver.1.1 criteria.
4. No prior chemotherapy, immunotherapy, and radiotherapy.
5. Life expectancy at least 3 months.
6. Patients who harbor UGT1A1\*1/\*1, \*1/\*6 or \*1/\*28.
7. The Eastern Cooperative Oncology Group (ECOG) performance status of =\<1.
8. Vital organ functions (listed below) are preserved within 14 days prior to entry.

   White blood cell count (WBC): \>= 3,000 per cubic millimeter Neu: \>= 1,500 per cubic millimeter Platelet count (PLT): \>= 100,000 per cubic millimeter Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT): \<= 100 IU/L, \<= 150 IU/L in cases with liver metastasis T-bil: \<= 1.5 mg/dL Serum creatinine: \<= 1.50 mg/dL Proteinuria: \<= 1+ Prothrombin time-international normalized ratio (PT-INR): \< 1.5
9. Written informed consent.

Exclusion Criteria:

1. Vermiform appendix cancer and anal canal cancer.
2. Administration of blood products/ granulocyte-colony stimulating factor (G-CSF), and blood transfusion within 14 days prior to enrollment.
3. Synchronous multiple malignancy or metachronous multiple malignancy less than 5 years disease free interval.
4. Hepatitis B virus antigen (HBs-Ag)(+), or hepatitis C virus antibody (HCV-Ab)(+).
5. History of severe allergy.
6. Sensory alteration or paresthesia interfering with function.
7. Prior radiotherapy for ilium and abdomen.
8. Infectious disease.
9. Uncontrolled diarrhea.
10. Ileus or bowel obstruction.
11. Interstitial lung disease or pulmonary fibrosis.
12. Malignant coelomic fluid required drainage.
13. Administration of atazanavir sulfate.
14. Heart disease to be clinically problem.
15. Major surgical procedure or intestinal resection within 28 days prior to enrollment or colostomy within 14 days prior to enrollment.
16. Known brain metastasis or strongly suspected of brain metastasis.
17. History of a thromboembolic disease.
18. Receiving anti-platelet drugs.
19. Poorly controlled gastrointestinal ulcer.
20. History of intestinal perforation within the past 12 months.
21. Poorly controlled hypertension.
22. Poorly controlled diabetes mellitus.
23. Severe mental disorders.
24. Women who are pregnant or nursing, men and women who wish to conceive a child or with no intention to contraception.
25. Any other cases who are regarded as inadequate for study enrollment by investigators.
Ultrasound-guidance for Intraosseous Access During Earthquake

The aim of this field report is to describe as the use ultrasound guidance can facilitate the insertion of intraosseous access, during the resuscitation, in the victims of out-of hospital traumatic cardiac arrest

The aim of this field report is to describe as the use ultrasound guidance can facilitate the insertion of intraosseous access, decreasing the time for drug administration and providing some benefits during the resuscitation, in the victims of out-of hospital traumatic cardiac arrest.

Eligibility Criteria:
Inclusion Criteria:

* traumatic cardiac arrest

Exclusion Criteria:

* non traumatic cardiac arrest
* beheading
* post-mortem hypostasis
* carbonized bodies
* dismembered bodies
Using MOVE! With Seriously Mentally Ill Veterans

This study involves a controlled trial of an optimized version of a weight management and physical activity psycho-educational intervention (called MOVE!) with 200 obese and overweight veterans with serious mental illness.

This study involves a controlled trial of an optimized version of a weight management and physical activity psycho-educational intervention (called MOVE!) for overweight and obese Veterans with serious mental illness. The study hypothesizes that MOVE! will result in weight loss and improved indicators of cardiovascular risk when compared to usual care. Medical outcomes are proportion achieving 4% or higher weight loss, mean weight loss, and reductions in cardiovascular risk (blood pressure, glucose and serum lipids). Psychosocial outcomes are general health, psychiatric functioning, quality of life, and self-esteem and medication adherence. Mediators include physical activity, dietary management, self-efficacy, and motivation/readiness to change. The intervention involves a well specified combination of individualized and group based services and draws on evidence based techniques and materials that are currently well packaged in an existing VA program called MOVE! The Comparison condition is operationalized as usual treatment plus monthly weight measurements and distribution of educational brochures regarding diet and exercise.

Eligibility Criteria:
Inclusion Criteria:

* DSM- IV diagnosis of schizophrenia spectrum disorders OR a DSM-IV diagnosis of other severe mental disorder including bipolar disorder, major depression, or severe anxiety disorder;
* Age between 18-64;
* No psychiatric hospitalization in 3-month period prior to enrollment;
* Community residency within 30 miles of either VA facility;
* A BMI of 25 or higher;
* Voluntary consent after receiving full information about the study;
* English speaking;
* Veteran of the armed forces

Exclusion Criteria:

* Active cancer other than non-melanoma skin cancer
* end stage chronic obstructive pulmonary disease
* end stage congestive heart failure
* end-stage neurological disorder
* problematic substance abuse as defined by provider
* end stage renal disease
* moderate to severe cognitive impairment (dementia, post-stroke)
* HIV positive with a CD4 count less than or equal to 350 within the last 6 months
* anorexia
* current pregnancy, currently nursing or planning to become pregnant in the next 6 months
* those living in long-term care facilities
* use in past 3 months of prescription pharmacological agents for weight loss
* no chart documented VA delivered medical primary care or general somatic care visit within the last 18 months
* most recent chart documented hematocrit level obtained within last six months is at or below 30%
* most recent chart documented creatinine level obtained within the last six months that is at or above 2.5
* most recent chart documented liver function tests obtained within the last six months exceeds twice the normal value for ALT, AST test in the Baltimore VA laboratory
Accuracy of Computer Guided Four Implants Placement in Completely Edentulous Mandible

Thirty-six completely edentulous healthy patients received four mandibular implants and were randomly divided into the following groups: (A) The implants were installed by fully guided stereolithographic stent (n = 18), and (B) The implants were installed by semi-guided stereolithographic stent. (n = 18). The accuracy analysis was performed by one experienced process engineer (DB). Cone beam computed tomography was performed before and after the surgical procedure to plan the virtual implant position and fabricate the surgical guide, as well as to determine implant position deviations. Both CBCT scans were superimposed, and the software compared preoperative linear and angular virtual measurements of planned implants with real measurements of the placed implants.

Objectives: Current study aimed to assess the accuracy of fully- guided implant placement in completely lower edentulous patients compared to the semi-guided protocol.

Materials and Methods: Thirty-six completely edentulous healthy patients received four mandibular implants and were randomly divided into the following groups: (A) The implants were installed by fully guided stereolithographic stent (n = 18), and (B) The implants were installed by semi-guided stereolithographic stent. (n = 18). The accuracy analysis was performed by one experienced process engineer (DB). Cone beam computed tomography was performed before and after the surgical procedure to plan the virtual implant position and fabricate the surgical guide, as well as to determine implant position deviations. Both CBCT scans were superimposed, and the software compared preoperative linear and angular virtual measurements of planned implants with real measurements of the placed implants. Measurements and analysis of results were performed by means of a software tool used during virtual planning (P3Dental; Protótipos).

Eligibility Criteria:
inclusion criteria:

* All patient wearing maxillary conventional denture.
* All patients had temporary mandibular overdenture supported by vertically inserted 4-implant at least six months ago.
* They were healthy, free from any systemic diseases relating to bone resorption such as uncontrolled diabetics or osteoporosis. This was achieved through medical history and clinical examination by physician.
* All patients are of angel's class I maxillo-mandibular relationships.

Exclusion Criteria:

* Patients had head and neck radiotherapy, patients with bleeding disorders or hepatic patients.
* Patients with metabolic disorders as diabetes mellitus, osteoporosis and hepatic disorders that might affect osseointegration.
* Long term immunosuppress and corticosteroid drug therapy.
* Patient with abnormal habits as clenching and bruxism.
* Smoking patient.
* Patient with problems in TMJ
From Skin Fibroblasts to Neural Stem Cells to Investigate in Vitro the Impact of Diabetes on Adult Neurogenesis

Obesity and glucose intolerance or overt diabetes are increasing at an alarming rate in the population, and are bound to become a public health issue and a major cause of disability, loss of independence and high social costs in the near future. A large body of evidence has in recent years highlighted, among the negative effects of overnutrition and glucose dysmetabolism, also an acceleration of cognitive decline and of brain senescence, through cellular (vascular, neuronal, or both) and molecular mechanisms still incompletely clarified. Understanding how overweight and impaired glucose homeostasis negatively affect brain function represents both a major scientific challenge and an avenue to early detection and possibly prevention of this invalidating complication. The aim of this project is to obtain neuronal progenitor-like cells from skin fibroblasts in order to correlate patient-specific metabolism to adult neural stem cell (NSC) and neuronal function in vitro.

* Analysis of skin fibroblasts from normal, obese, lean/diabetic and obese/diabetic individuals and in vitro epigenetic conversion, as revealed by morphological changes, loss of mesenchymal markers and expression of pluripotency genes.
* To re-differentiate patient-derived pluripotent cells into neural progenitor (NP) and to test their proliferative, self-renewal and multilineage differentiation capacity.
* To evaluate neuronal cells derived from patient and control pluripotent cells for a number functional and biochemical parameters (apoptosis/autophagy, mitochondrial potential, reactive oxygen species etc.) relevant to neurodegenerative disorders.

Eligibility Criteria:
Inclusion Criteria:

* Patients of both sexes with BMI \< 25 (normal weight) and BMI \> 30 (obese) with or without T2DM with an indication for surgery

Exclusion Criteria:

* Malignant neoplastic diseases
Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition

Within this study patient data are collected from different imaging and motion monitoring devices that will be used to develop and test strategies for image-guided adaptive radiotherapy in cervix cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis of cervix cancer
* Prescription of radiation treatment to the primary cancer

Exclusion Criteria:

* Prior radiation treatment to the pelvis
Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia

The purpose of the questionnaire is to find risk factors for the development of post-traumatic stress disease (PTSD) in health workers during COVID-19 pandemy.


Eligibility Criteria:
Inclusion Criteria:

* workers in health services, including phisicians, nurses, inhospital technicians and biologists